Multiple evidence have indicated that GPR34 has elevated expression level in malignancies, such as gastric cancer, glioma, TNBC, and MALT lymphoma, and contributes to the pathogenesis and progression of these cancers [23, 26–28], while the expression level and oncogenic role of GPR34 in ATC remain poorly understood. Here, GPR34 is linked to central nervous system cancer.